Beijing, China

Xiaobing Lv

This inventor holds 1 USPTO granted patent. Top assignee: Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xiaobing Lv. Retrieved from https://idiyas.com/inventor/xiaobing-lv

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Xiaobing Lv: Inventor of Novel Cationic Lipid Compounds

Introduction

Xiaobing Lv is an inventor based in Beijing, China. His patent work includes pharmaceutical compounds and their potential use in delivering therapeutic or prophylactic agents.

Latest Patents

Lv is associated with 1 patent, titled “Long-acting low-toxicity novel cationic lipid compounds and composition thereof.” The invention describes novel cationic lipid compounds represented by formula (I), as well as their N-oxides, solvates, pharmaceutically acceptable salts, and stereoisomers. It also covers compositions containing these compounds and their use to deliver therapeutic or prophylactic agents.

Career Highlights

Lv is associated with Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. His patent reflects work in pharmaceutical innovation, particularly in developing lipid compounds and compositions for agent delivery.

Collaborations

The patent information names Gengshen Song and Honglei Zhang as Lv’s coworkers, indicating collaboration in this area of pharmaceutical research and development.

Conclusion

Xiaobing Lv’s patent activity centers on novel cationic lipid compounds and their potential applications in delivering therapeutic or prophylactic agents.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…